ReviewThe Journal of clinical endocrinology and metabolism2019
Clinical and Pathological Aspects of Silent Pituitary Adenomas.
Review in The Journal of clinical endocrinology and metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 1 synthesis or guideline pooled it, 195 citations in OpenAlex.
- Clinical Relevance of Genetic Analysis in Patients With Pituitary Adenomas: A Systematic Review.Frontiers in endocrinology · 2019Pooled it
- Clinical characteristics and prognostic outcomes of silent corticotroph versus gonadotroph adenomas: A 603-case single-center cohort study.Neurosurgical review · 2026Article
- Pituitary neuroendocrine tumors: imaging features, clinical relevance, and a proposal for standardized MRI reporting.Neuroradiology · 2026Review
- Disentangling secretory ambiguity and the limitations of classical thresholds in defining prolactinomas.Pituitary · 2026Article
- Inflammation, oxidative stress and purinergic signaling in pituitary neuroendocrine tumors (PitNETs).Purinergic signalling · 2026Review
- Constant ovulation during oral contraceptive treatment: Follicle-stimulating hormone-secreting pituitary adenoma case report and literature review.Journal of family medicine and primary care · 2026Article
- Molecular biology of pituitary neuroendocrine tumors.Journal of neuro-oncology · 2026Review
- Characterization of the secretory profile of gonadotroph pituitary tumors.Journal of endocrinological investigation · 2026Article
- Clinicopathological features and outcomes in non-functioning pituitary neuroendocrine tumors: a transcription factor-driven subtype analysis.Journal of neuro-oncology · 2026Article
- Association between the WHO 2017 and 2022 classification updates and ICD-10 code accuracy in patients with PitNETs: a real-world retrospective study.BMC endocrine disorders · 2026Article
- Machine Learning-Driven PCDI Classifier for Invasive PitNETs.Current gene therapy · 2026Article
- Differential expression of POMC-processing genes in corticotroph tumors.Endocrine oncology (Bristol, England) · 2026Article
- Mast cells act as pro-angiogenic and pro-tumorigenic players in pituitary gonadotroph tumors.Neuro-oncology · 2026Article
- Magnetic resonance imaging-based morphometric differences in the normal pituitary gland with functional and nonfunctional pituitary adenomas.Surgical neurology international · 2026Article
- Pathological Classification and Clinical Characteristics of Growth Hormone-Secreting PitNETs.Neuroendocrinology · 2026Article
- DHEAS Elevation as the Early Biochemical Abnormality in ACTH-Secreting Pituitary Microadenomas in Children: Two Case Reports.Endocrine, metabolic & immune disorders drug targets · 2026Article
- Clinical, radiological, and pathological characteristics and long-term outcomes of silent corticotroph adenomas: a retrospective study.BMC endocrine disorders · 2025Article
- Challenges in the Management of Silent Lactotroph Pituitary Adenoma.JCEM case reports · 2025Article
- DNA methylation profiling of pituitary neuroendocrine tumors identifies distinct clinical and pathological subtypes based on epigenetic differentiation.Neuro-oncology · 2025Article
- Silent growth hormone pituitary adenomas: a single-center study.Pituitary · 2025Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
contextSilent pituitary adenomas are anterior pituitary tumors with hormone synthesis but without signs or symptoms of hormone hypersecretion. They have been increasingly recognized and represent challenging diagnostic issues. EVIDENCE ACQUISITION: A comprehensive literature search was performed using MEDLINE and EMBASE databases from January 2000 to March 2018 with the following key words: (i) pituitary adenoma/tumor and nonfunctioning; or (ii) pituitary adenoma/tumor and silent. All titles and abstracts of the retrieved articles were reviewed, and recent advances in the field of silent pituitary adenomas were summarized. EVIDENCE SYNTHESIS: The clinical and biochemical picture of pituitary adenomas reflects a continuum between functional and silent adenomas. Although some adenomas are truly silent, others will show some evidence of biochemical hypersecretion or could have subtle clinical signs and, therefore, can be referred to as clinically silent or "whispering" adenomas. Silent tumors seem to be more aggressive than their secreting counterparts, with a greater recurrence rate. Transcription factors for pituitary cell lineages have been introduced into the 2017 World Health Organization guidelines: steroidogenic factor 1 staining for gonadotroph lineage; PIT1 (pituitary-specific positive transcription factor 1) for growth hormone, prolactin, and TSH lineage, and TPIT for the corticotroph lineage. Prospective studies applying these criteria will establish the value of the new classification.
conclusionsA concise review of the clinical and pathological aspects of silent pituitary adenomas was conducted in view of the new World Health Organization classification of pituitary adenomas. New classifications, novel prognostics markers, and emerging imaging and therapeutic approaches need to be evaluated to better serve this unique group of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.